Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Tofogliflozin may improve insulin secretory capacity in some type 2 diabetes patients
Última actualización 18 de julio de 2026
Key finding
HbA1c decreased significantly from baseline.
This study evaluated the short-term effects of tofogliflozin on insulin secretory capacity in type 2 diabetes. It found significant improvements in several metabolic markers.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the short-term effects of tofogliflozin on insulin secretory capacity in type 2 diabetes. It found significant improvements in several metabolic markers.
Clinical relevance
These findings are important as they suggest that tofogliflozin may offer additional benefits beyond standard diabetes management, particularly in improving liver health. This could have implications for treatment strategies in patients with type 2 diabetes, especially those at risk for fatty liver disease.
Keep in mind
The study's short duration may limit long-term applicability of findings. Sample size and demographic diversity were not detailed, affecting generalizability. The disposition index did not show significant changes, indicating potential limitations in assessing insulin secretory capacity.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Maiko M, Aika M, Akinobu N, et al. Short-term effects of tofogliflozin on insulin secretory capacity in type 2 diabetes: a randomized controlled trial. Journal of Diabetes Investigation. 2026;17(4):627-635. doi:10.1111/jdi.70245
Efectos Principales
HbA1c decreased by 0.2% (p=0.0001) from baseline.
Glycated albumin decreased by 0.8% (p=0.006) from baseline.
Fasting plasma glucose decreased by 13.5 mg/dL (p=0.0001) from baseline.
The fatty liver index improved significantly more in the tofogliflozin group.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Metformin, Tofogliflozin and Disposition Index, Fasting Plasma Glucose (FPG), Fatty liver index, and 2 more.
This study contributes evidence to
Primary intervention
Metformin
Primary outcomes
- Disposition Index
- Fasting Plasma Glucose (FPG)
- Fatty liver index
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
10
Evidence pairs
10
Relationships
4
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
4
Related topics
10
Evidence pairs
776
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 10 evidence relationships
- Includes primary outcome data
- Linked to 4 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Metformin Therapies and Fasting Glucose
Evidencia relacionada
Relación de evidencia
Metformin Therapies and HbA1c
Guardar evidencia
Tema de evidencia
Insulin Resistance
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Fasting Plasma Glucose (FPG)
Metformin → Fasting Plasma Glucose (FPG)
Metformin → Fasting Plasma Glucose (FPG)
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 90
- Very Positive
- ConsistencyScore™
- 80
- consistent
Estudios de apoyo: Basado en 5 estudios
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 82
- Positive
- ConsistencyScore™
- 67
- generally_consistent
Estudios de apoyo: Basado en 11 estudios
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerFasting Plasma Glucose (FPG)
Tofogliflozin → Fasting Plasma Glucose (FPG)
Tofogliflozin → Fasting Plasma Glucose (FPG)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 2 estudios
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- HbA1c decreased significantly by 0.2%, indicating improved blood sugar control.
- Fasting plasma glucose levels dropped by 13.5 mg/dL, showing enhanced metabolic response.
- Fatty liver index improved more in the tofogliflozin group, suggesting better liver health.
A quién se aplica
- Adults diagnosed with type 2 diabetes.
- Patients at risk for fatty liver disease.
Tener en Cuenta
- Results are based on a short-term study; long-term effects remain uncertain.
- Findings may not be applicable to all populations due to potential demographic limitations.
- The study did not measure all possible confounding factors that could influence outcomes.
Entre Líneas
- The study's short duration may limit long-term applicability of findings.
- Sample size and demographic diversity were not detailed, affecting generalizability.
- The disposition index did not show significant changes, indicating potential limitations in assessing insulin secretory capacity.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Metformin Therapies and HbA1c, Metformin Therapies and Fasting Glucose.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Metformin Therapies → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 82
- Positive
- ConsistencyScore™
- 67
- generally_consistent
Estudios de apoyo: Basado en 11 estudios
View evidenceMedications
Metformin Therapies → Fasting Glucose
Medications
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 90
- Very Positive
- ConsistencyScore™
- 80
- consistent
Estudios de apoyo: Basado en 5 estudios
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
HbA1c Evidence Hub
All studies measuring HbA1c
11 studies
outcome_hubMeasures HbA1c as a key outcome.
Metformin Therapies Evidence Hub
All studies on Metformin Therapies
11 studies
intervention_hubContributes to Metformin Therapies evidence base.
Fasting Glucose Evidence Hub
All studies measuring Fasting Glucose
5 studies
outcome_hubMeasures Fasting Glucose as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Metformin and HbA1c
Intervention: MetforminOutcome: HbA1c
11 results
All studies on Metformin and Fasting Plasma Glucose (FPG)
Intervention: MetforminOutcome: Fasting Plasma Glucose (FPG)
5 results
All studies on Metformin
Intervention: Metformin
11 results
All studies measuring HbA1c
Outcome: HbA1c
11 results
All studies measuring Fasting Plasma Glucose (FPG)
Outcome: Fasting Plasma Glucose (FPG)
5 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Metformin Therapies improve fasting glucose?
Strong Evidence
Metformin Therapies may improve Fasting Glucose.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Fasting Plasma Glucose (FPG)
EvidenceScore™ Strong | EvidenceScore™ 83.2 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 8 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Metformin Therapies improve HbA1c?
Strong Evidence
Metformin Therapies appears to improve HbA1c.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.2 | moderate positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 13 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Tofogliflozin improve HbA1c?
Moderate Evidence
Tofogliflozin appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Population details are unavailable.
Does Metformin improve fatty liver index?
Emerging Evidence
Metformin appears to improve Fatty liver index.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Fatty liver index
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Vildagliptin and Metformin Improve Glycemic Control in Type 2 DiabetesHRS-7535 improves glycemic control in adults with type 2 diabetesEarly use of effective therapies may improve diabetes outcomesPremeal metformin improves postmeal glucose control in diabetes.Metformin may reduce prandial insulin needs in pregnant women with type 1 diabetes
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.